Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid ...
Mechanistic models and hypothesis-driven strategies generate optimized efficient solutions for drug development, says ...
In particular, Konagurthu says, AI/ML can help sift through a field of drug candidates in which the percentage that are ...
Using Ascletis' proprietary Ultra-Long-Acting Platform technology, co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly ...
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the ...
Stockhead on MSN
Biocurious: Inhalerx hones in on pot for pain and panic in its quest for historic drug approval
Minnow Inhalerx hopes to be first to market with inhaled synthetic medical cannabis therapies for cancer pain and panic ...
The approval puts Lunsumio on the same footing as Epkinly (epcoritamab) in FL – a form of non-Hodgkin lymphoma (NHL) – as ...
The FDA's push for lower-cost medicines looks good on paper, but the patent office under President Trump may be going in the ...
OneSource Specialty Pharma has raised its FY28 revenue forecast from $400 million to over $500 million, driven by strong ...
Company to offer the first clinically validated dietary management of sarcopenia, now available for GLP-1 muscle loss, positioning Wellgistics to help 6,500+ independent pharmacy network (‘Pharmacy ...
Rafa Laboratories secured a BARDA contract to develop an intramuscular TXA injection for prehospital bleeding care.
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback